Payment overview · 2025
General Payments
$268.31
11 reported records · 6 companies
Healthcare provider profile · identity verified
Thomas St Clair Williams, MD
Allopathic & Osteopathic Physicians|Family Medicine · MONROE, LA · NPI 1467422048
Verified facts
What the public records show
CMS Open Payments records show Thomas St Clair Williams, MD received $268.31 in general payments during 2025 across 11 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 35.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $96.00 | 35.8% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $78.22 | 29.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $39.41 | 14.7% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $19.39 | 7.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.67 | 7.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.62 | 6.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $268.31 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $96.00 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $78.22 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $39.41 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 94 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 187 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
94 | 29 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
187 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 656 | 146 |
| Potassium Chloride | Potassium Chloride | 475 | 105 |
| Omeprazole | Omeprazole | 440 | 104 |
| Furosemide | Furosemide | 414 | 91 |
| Levothyroxine Sodium | Levothyroxine Sodium | 398 | 68 |
| Gabapentin | Gabapentin | 385 | 96 |
| Amlodipine Besylate | Amlodipine Besylate | 358 | 93 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 304 | 76 |
| Eliquis | Apixaban | 275 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 257 | 77 |
| Montelukast Sodium | Montelukast Sodium | 256 | 53 |
| Lisinopril | Lisinopril | 251 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 236 | 66 |
| Clopidogrel | Clopidogrel Bisulfate | 224 | 52 |
| Mounjaro | Tirzepatide | 222 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 188 | 39 |
| Prednisone | Prednisone | 188 | 70 |
| Jardiance | Empagliflozin | 187 | 30 |
| Donepezil Hcl | Donepezil Hcl | 177 | 29 |
| Trazodone Hcl | Trazodone Hcl | 176 | 39 |
| Valsartan | Valsartan | 175 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 164 | 38 |
| Losartan Potassium | Losartan Potassium | 163 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 154 | 57 |
| Ozempic | Semaglutide | 153 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 150 | 43 |
| Sertraline Hcl | Sertraline Hcl | 145 | 27 |
| Nifedipine Er | Nifedipine | 138 | 34 |
| Tramadol Hcl | Tramadol Hcl | 138 | 39 |
| Metformin Hcl | Metformin Hcl | 136 | 39 |
| Clonidine Hcl | Clonidine Hcl | 130 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 130 | 34 |
| Carvedilol | Carvedilol | 119 | 31 |
| Metformin Hcl Er | Metformin Hcl | 118 | 35 |
| Famotidine | Famotidine | 117 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 115 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 109 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 108 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 98 | 18 |
| Farxiga | Dapagliflozin Propanediol | 94 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 92 | 19 |
| Glimepiride | Glimepiride | 91 | 22 |
| Celecoxib | Celecoxib | 89 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 86 | 19 |
| Allopurinol | Allopurinol | 83 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 77 | 27 |
| Meloxicam | Meloxicam | 77 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 77 | 17 |
| Glipizide | Glipizide | 76 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 76 | 17 |
| Azithromycin | Azithromycin | 73 | 58 |
| Warfarin Sodium | Warfarin Sodium | 73 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 68 | 13 |
| Simvastatin | Simvastatin | 68 | 15 |
| Clonazepam | Clonazepam | 67 | 12 |
| Ezetimibe | Ezetimibe | 67 | 23 |
| Lovastatin | Lovastatin | 67 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 66 | 43 |
| Nystatin | Nystatin | 65 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 64 | 22 |
| Levofloxacin | Levofloxacin | 63 | 51 |
| Spironolactone | Spironolactone | 63 | 13 |
| Buspirone Hcl | Buspirone Hcl | 62 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 60 | 20 |
| Topiramate | Topiramate | 60 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 59 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 16 |
| Finasteride | Finasteride | 56 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 56 | 18 |
| Atenolol | Atenolol | 55 | 12 |
| Linzess | Linaclotide | 55 | 15 |
| Myrbetriq | Mirabegron | 53 | suppressed |
| Pregabalin | Pregabalin | 53 | 12 |
| Hydrocortisone | Hydrocortisone | 52 | 18 |
| Meclizine Hcl | Meclizine Hcl | 52 | 22 |
| Silver Sulfadiazine | Silver Sulfadiazine | 52 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 39 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 49 | 40 |
| Baclofen | Baclofen | 49 | 17 |
| Entresto | Sacubitril/Valsartan | 49 | suppressed |
| Levetiracetam | Levetiracetam | 49 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 48 | 32 |
| Xarelto | Rivaroxaban | 46 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 45 | 12 |
| Glipizide Er | Glipizide | 45 | suppressed |
| Memantine Hcl | Memantine Hcl | 45 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Mupirocin | Mupirocin | 43 | 29 |
| Sucralfate | Sucralfate | 43 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 35 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 31 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 41 | suppressed |
| Colchicine | Colchicine | 41 | 16 |
| Fluconazole | Fluconazole | 40 | 31 |
| Ibandronate Sodium | Ibandronate Sodium | 40 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 40 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | 12 |
| Estradiol | Estradiol | 37 | suppressed |
| Naproxen | Naproxen | 37 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 35 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Trulance | Plecanatide | 35 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | 15 |
| Methylprednisolone | Methylprednisolone | 33 | 25 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 32 | 16 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 32 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 30 | suppressed |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | 11 |
| Cefdinir | Cefdinir | 28 | 22 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 20 |
| Dapagliflozin | Dapagliflozin Propanediol | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 26 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | 11 |
| Diazepam | Diazepam | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 25 | 15 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Novolog | Insulin Aspart | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | 11 |
| Ondansetron Odt | Ondansetron | 21 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Metolazone | Metolazone | 20 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 19 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | 12 |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Rivastigmine | Rivastigmine | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Fycompa | Perampanel | 14 | suppressed |
| Perphenazine | Perphenazine | 14 | suppressed |
| Phenytoin | Phenytoin | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Entacapone | Entacapone | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Kerendia | Finerenone | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Cozaar | Losartan Potassium | 11 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $268.31 · 11 records | Bayer Healthcare Pharmaceuticals Inc. | EVENITY, FARXIGA, JARDIANCE, Kerendia, Omnipod, VERQUVO | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error